MedTrace Logo

Skin Cancer and Hyperthermia and Radiotherapy

NCT06384053 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-06-15

No results posted yet for this study

Summary

The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).

Conditions

Interventions

COMBINATION_PRODUCT

Water-filtered infrared-A-hyperthermia (wIRA) hyperthermia combined

The wIRA device applies hyperthermia by heating the treatment area (with maximum surface temperature set to 43° C), aiming to make cancer cells more sensitive to radiation therapy for non-melanoma skin cancer combined with radiotherapy.

RADIATION

Radiotherapy (RT)

Radiotherapy is applied.

Sponsors & Collaborators

  • Luzerner Kantonsspital

    collaborator OTHER

  • Lindenhofgruppe AG

    collaborator INDUSTRY

  • Kantonsspital Aarau

    collaborator OTHER

  • Kantonsspital Winterthur KSW

    lead OTHER

Principal Investigators

  • Winfried Arnold, Dr.med.univ.(A) · Luzerner Kantonsspital

  • Maximilian Sturz, Dr.med. · Luzerner Kantonsspital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-07-01
Completion
2028-07-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06384053 on ClinicalTrials.gov